Lev Gerlovin is a speaker during the session titled “Assess Value When Innovating to Establish Greater Benefits Relative to Costs.”
For more information on this event, click here.
Keytruda and PD(L)1: Life after programmed death (part 2)
Looking ahead, we see a proliferation of PD-(L)1’s role; particularly in uses that go beyond traditional monoclonal, single-target antibodies (mAbs). Not only...